In this study, we are the first to show that the bioflavonoid API reduces tumor-associated inflammatory factors, restores SHIP-1 expression and augments tumoricidal TAM, which corresponds with an increase in anti-tumor immune responses in different pre-clinical PC models. This evidence concerns the gene INPP5D and pachyonychia congenita.